Founded in 2015 by a team responsible for the FDA’s approval of the world’s first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies. Alpine Immune Sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases.
TypePrivate
HQSeattle, US
Founded2015
Websitealpineimmunesciences.com
Alpine Immune Sciences was founded in 2015 and is headquartered in Seattle, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Alpine Immune Sciences

Mitchell H. Gold

Mitchell H. Gold

Executive Chairman & CEO
Mark Litton

Mark Litton

President & Chief Operating Officer
Stanford Peng

Stanford Peng

Executive VP of R&D, Chief Medical Officer
Kristine Swiderek

Kristine Swiderek

Senior VP of Research
Paul Rickey

Paul Rickey

CFO
Show more

Alpine Immune Sciences Office Locations

Alpine Immune Sciences has an office in Seattle
Seattle, US (HQ)
200 Elliott Avenue West
Show all (1)
Report incorrect company information

Alpine Immune Sciences Financials and Metrics

Summary Metrics

Founding Date

2015

Alpine Immune Sciences total Funding

$49.3 m

Alpine Immune Sciences latest funding size

$48 m

Time since last funding

2 years ago

Alpine Immune Sciences investors

Alpine Immune Sciences's latest funding round in June 2016 was reported to be $48 m. In total, Alpine Immune Sciences has raised $49.3 m
Show all financial metrics

Alpine Immune Sciences Revenue

Alpine Immune Sciences's revenue was reported to be $1.73 m in FY, 2017 which is a 41.3% decrease from the previous period.
USD

EBIT (Q2, 2018)

(14.0m)

Cash (30-Jun-2018)

3.6m
USDFY, 2015FY, 2016FY, 2017

Revenue

492.0k3.0m1.7m

Revenue growth, %

500%(41%)

General and administrative expense

441.0k1.1m6.1m

R&D expense

422.0k3.0m10.6m
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

25.0m11.8m8.0m

Prepaid Expenses

432.0k36.0k1.3m

Current Assets

87.7m11.9m82.5m

PP&E

223.0k740.0k1.1m
Quarterly
USDQ2, 2018

Cash

3.6m

Current Assets

71.8m

PP&E

1.2m

Total Assets

73.1m
USDQ2, 2018

Net Income

(13.2m)

Depreciation and Amortization

170.0k

Accounts Payable

557.0k

Cash From Operating Activities

(11.6m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Alpine Immune Sciences Online and Social Media Presence

Embed Graph
Report incorrect company information

Alpine Immune Sciences Blogs

Alpine Immune Sciences to Present at Society for Immunotherapy of Cancer 33rd Annual Meeting

SEATTLE --(BUSINESS WIRE)--Oct. 4, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced two upcoming poster presentations at the Society for

Alpine Immune Sciences to Present at Ladenburg Thalmann 2018 Healthcare Conference

Alpine Immune Sciences to Present at Ladenburg Thalmann 2018 Healthcare Conference Content Import Tue, 09/25/2018 - 07:02 Alpine Immune Sciences to Present at Ladenburg Thalmann 2018 Healthcare Conference September 25, 2018 This release is a backfill from a N…

Alpine Immune Sciences Announces Upcoming Scientific Presentations

ALPN-101 preclinical data to be presented at the 2018 ACR/ARHP Annual Meeting and the 143 rd Annual Meeting of the American Neurological Association SEATTLE --(BUSINESS WIRE)--Sep. 24, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing

Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2018 Financial Results

SEATTLE --(BUSINESS WIRE)--Aug. 9, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, provided a corporate update and

Alpine Immune Sciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE --(BUSINESS WIRE)--Aug. 8, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory and other diseases, today reported the grant of an equity inducement award to Mark Litton ,

Alpine Immune Sciences to Present at 2018 Wedbush PacGrow Healthcare Conference

SEATTLE--( BUSINESS WIRE )--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, today announced the company will present a business overview and update at the 2018
Show more

Alpine Immune Sciences Company Life and Culture

Report incorrect company information